Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease

• Published in: NPJ Parkinson's Disease Vol. 8; no. 1; p. 57
• Main Authors: Lee, Young-gun, Jeong, Seong Ho, Park, Mincheol, Kang, Sung Woo, Baik, Kyoungwon, Jeon, Seun, Lee, Phil Hyu, Sohn, Young Ho, Ye, Byoung Seok
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.05.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/208/1516; 692/53/2421; Alzheimer's disease; Biomarkers; Biomedical and Life Sciences; Biomedicine; Health risk assessment; Neurology; Neurosciences; Parkinson's disease
• ISSN: 2373-8057; 2373-8057
• DOI: 10.1038/s41531-022-00317-8

Coexisting Alzheimer’s disease (AD) pathology is common in Parkinson’s disease (PD). However, the implications of genetic risk scores (GRS) for AD have not been elucidated in PD. In 413 de novo PD and 195 healthy controls from the Parkinson’s Progression Marker Initiative database, the effects of GRS for AD (GRS-AD) and PD (GRS-PD) on the risk of PD and longitudinal CSF biomarkers and clinical outcomes were explored. Higher GRS-PD and lower baseline CSF α-synuclein were associated with an increased risk of PD. In the PD group, GRS-AD was correlated positively with CSF p-tau/Aβ and negatively with CSF α-synuclein. Higher GRS-PD was associated with faster CSF p-tau/Aβ increase, and GRS-AD and GRS-PD were interactively associated with CSF α-synuclein. In the PD group, higher GRS-AD was associated with poor visuospatial function, and baseline CSF p-tau/Aβ was associated with faster cognitive decline. Higher GRS-PD was associated with better semantic fluency and frontal-related cognition and motor function given the same levels of CSF biomarkers and dopamine transporter uptake. Taken together, our results suggest that higher GRS-AD and CSF p-tau/Aβ, reflecting AD-related pathophysiology, may be associated with cognitive decline in PD patients.